- Risk assessments using real larval data confirm that the chronic risk assessment for adults is the key driver of honey bee risk in the EFSA Bee GD as stated in the original impact analysis.
- Based on the data with different larval endpoints it can be concluded that larval tests providing D7/D8 endpoints can be used in the risk assessment for non-toxic compounds.
- The high failure rate on insecticides for honey bees jeopardize their registration, as risks cannot be resolved by unworkable higher tier studies.
- Almost all compounds and their respective products will fail the bumble bee and solitary bee larval risk assessment, because valid laboratory methods on their larvae are not available and higher tier studies are long-term research projects.
- The need to develop internationally recognised guidelines remains. New guidance should be built on existing guidance, recent research results as well as experiences and recommendations of all stakeholders